<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: Re: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rafal@smigrodzki.org)">
<meta name="Subject" content="Re: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-15">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>Re: Performance enhancement with selegiline</h1>
<!-- received="Sat Feb 15 22:18:21 2003" -->
<!-- isoreceived="20030216051821" -->
<!-- sent="Sun, 16 Feb 2003 00:18:17 -0500" -->
<!-- isosent="20030216051817" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rafal@smigrodzki.org" -->
<!-- subject="Re: Performance enhancement with selegiline" -->
<!-- id="003301c2d57a$d16ccc90$6401a8c0@dimension" -->
<!-- charset="iso-8859-1" -->
<!-- inreplyto="Pine.LNX.4.44.0302151453080.12464-100000@server.aeiveos.com" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rafal@smigrodzki.org?Subject=Re:%20Performance%20enhancement%20with%20selegiline"><em>rafal@smigrodzki.org</em></a>)<br>
<strong>Date:</strong> Sat Feb 15 2003 - 22:18:17 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2784.html">Michael M. Butler: "Evil Emanations? was Re: self censorship urged on science journalists"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2782.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<li><strong>In reply to:</strong> <a href="2767.html">Robert J. Bradbury: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2782.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2783">[ date ]</a>
<a href="index.html#2783">[ thread ]</a>
<a href="subject.html#2783">[ subject ]</a>
<a href="author.html#2783">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
----- Original Message -----
<br>
From: &quot;Robert J. Bradbury&quot; &lt;<a href="mailto:bradbury@aeiveos.com?Subject=Re:%20Performance%20enhancement%20with%20selegiline">bradbury@aeiveos.com</a>&gt;
<br>
<p><em>&gt; The only way medicine and lifespan extension science is going to
</em><br>
<em>&gt; make progress is to work its way out of the box that one size fits
</em><br>
<em>&gt; all.  The best progress we might make is to acknowledge those situations
</em><br>
<em>&gt; in which an individuals perspective may indeed be valid.  Should a
</em><br>
<em>&gt; physician reject a treatment with which one in a million lives
</em><br>
<em>&gt; might be saved?
</em><br>
<p>### If you can predict exactly which patient will benefit, it's great, which
<br>
is why I am so eager to hear about any progress from US Genomics, or
<br>
Perlegen.
<br>
<p>If you can't find the one-in-a-million guy, your NNT will be one million,
<br>
making the drug perfectly useless.
<br>
<p>Hopefully, by the time I retire, we will have full diagnostic resequencing
<br>
of every patient's genome, so the latter situation would not occur.
<br>
<p>Rafal
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2784.html">Michael M. Butler: "Evil Emanations? was Re: self censorship urged on science journalists"</a>
<li><strong>Previous message:</strong> <a href="2782.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<li><strong>In reply to:</strong> <a href="2767.html">Robert J. Bradbury: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2782.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2783">[ date ]</a>
<a href="index.html#2783">[ thread ]</a>
<a href="subject.html#2783">[ subject ]</a>
<a href="author.html#2783">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sat Feb 15 2003 - 22:20:31 MST
</em></small></p>
</body>
</html>
